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CHAPTER 1
LITERATURE REVIEW
Infectious Laryngotracheitis
Infectious laryngotracheitis (ILT) is an acute disease of
chickens characterized by signs of respiratory depression,
gasping, and expectoration of bloody exudate.  Although the
disease affects all ages, the most characteristic signs are
observed in adult birds.
History
Infectious laryngotracheitis was first described in 1925,
and the outbreak on which that report was based occurred in
October and November of 1923  (May & Tittsler, 1925).  Some
reports speculate that the disease may have existed earlier,
as an unusual high mortality among live poultry was observed.
Investigations were made and finally it was concluded that the
losses  were due to a disease which, if not new had not been
previously extensively studied (Beach, 1926).
In some poultry periodicals, it has been stated that ILT
was introduced into the United States by show birds from
Canada in 1921 (Beach, 1926).  The first authentic report of2 
its occurrence in the United States, involved a Rhode Island
flock in November, 1923 (May & Tittsler, 1925).  The etiology
of the disease was undetermined,  and it was thought that
mortality could be due to  exposure to cold (May & Tittsler,
1925).  The disease was transmitted to healthy birds by means
of a throat swab from dead birds (Graham, et al., 1930; May &
Tittsler, 1925).
Old  names  for  ILT  include  infectious  bronchitis,
infectious tracheitis, tracheo-laryngitis, chicken "flu" and
Canadian "flu" (Beach, 1926).  The term laryngotracheitis was
used as early as 1930 (Beach, 1930; Graham, et al., 1930) and
the name infectious laryngotracheitis was adopted in 1931 by
the Special Committee on Poultry Diseases of the American
Veterinary Medical Association.  A mild form of ILT was
reported and designated as the subacute or chronic form of the
disease (Graham, et al., 1930).  The cause of ILT was first
shown to be a filterable virus in 1930 (Beaudette, 1930).
Classification
Infectious laryngotracheitis has been identified in most
countries.  It is a serious disease of chickens  in the United
States, Europe, and Australia.  Infectious laryngotracheitis
virus  has  all  the  characteristics  of  the  family
Herpesviridae.  The virus  is  cuboidal,  enveloped,  ether
sensitive, and contains a core composed of DNA.  ILTV is  a
member of the subfamily Alphaherpesvirinae  (Roizman, 1982).
In the last 50 years, more than 80 distinct herpesviruses have3 
been isolated from a wide variety of animal species.  These
herpesviruses  share  structural  features  (Roizman,  1982).
"Herpes" is a Greek word which means "creep".  The term herpes
was used in medicine to describe a variety of skin conditions
and diseases for at least 25 centuries (Roizman, 1982).  In
recent years the known membership of the herpes group has
increased considerably.  Twenty or more members  share the
following properties (a) a genome of double stranded DNA (b)
a regular icosahedral capsid made of 162 capsomeres and often
surrounded  by  a  lipid-containing  envelope,  and  (c)
intranuclear assembly of the capsid around the genome.
Morphology
Electron microscopic examination reveals  icosahedral
viral particles in infected chicken embryo cells.  These
particles are similar in  structure to herpes simplex virus.
The hexagonal virion is 80-100 nm in diameter.  There are
three main structural components: the core, the capsid, and
the envelope.  The envelope is 195-250 nm in diameter and has
fine projections at the periphery of its membrane  (Watrach,
et al., 1963).  The capsid  has icosahedral symmetry and is
composed of 162 elongated hollow capsomeres.  The diameter of
a complete virus particle is 195-250 nm (Cruickshank, et al.,
1963; Watrach, et al., 1963).
Virus Replication
Replication of ILTV is similar to that of herpes simplex
and pseudorabies virus.  Virus  enters  into  the  cell by4 
pinocytosis after being adsorbed on the cell surface.  Rate of
adsorption depends on the volume of inoculum and cell system.
Enveloped particles adsorb more readily than naked particles
(Holmes & Watson, 1963).
Once inside the cells, host enzymes disrupt the envelope
and capsid of ILTV and its DNA is released.  Viral DNA
migrates  to  the  cell  nucleus.  After  10-12  hours  ILTV
components can be observed in the nucleus.  A sharp rise in
intracellular virus content occurs after 12 hours of infection
and a maximum virus titer is found between 30 and 36 hours of
infection.  Virus  titer gradually diminishes  thereafter
(Reynolds, et al., 1968).
The viral envelope is formed as the nucleocapsid migrates
through the cell's nuclear membrane.  The enveloped virus
particles accumulate in a vacuolar membrane in the cytoplasm.
Then the vacuoles containing virus particles migrate to the
plasma membrane and  are released after  disruption of the
cell membrane (Nii, et al., 1968).  A maximum titer of ILTV
reaching 106 plaque forming units/ml of tracheal exudate is
found on the third day after inoculation of 8-week-old white
leghorn chickens.  Virus may also be isolated from the lungs
and livers of infected chickens but virus titers are low in
those organs (Chang, et al.,1973).
Resistance to Chemical and Physical Agents
Infectious laryngotrachetis virus particles are sensitive
to lipolytic agents, heat, and various disinfectants.5 
A solution of 3% cresol or 1% lye can inactivate LTV in less
than  1  min.  ILTV can survive  for  a  long period when
lyophilized or kept at -20 to -60 C (Goldhaft, 1961).
Strain Classification
Most of the ILTV strains appear antigenically similar
based on  virus neutralization  (VN)  or immunofluorescence
tests (IFT) using reference-specific antiserum. Some strains,
however,  have  been  neutralized poorly by  such antisera
(Burnet, 1936; Pulsford & Stokes, 1953).  Some other workers
have also suggested there is minor antigenic variation among
the strains of ILTV (Russell & Turner, 1983; Shibley, et al.,
1962).
In attempts to find useful techniques for differentiating
the  antigenically-similar  strains  of  ILTV,  restriction
endonucleases have been used to study the viral DNA.  On the
basis  of  these  findings  some  ILTV  strains  have  been
classified.  Differences in DNA fragment patterns have been
found between an Australian vaccine strain and a field strain
by this method (Kotiw, et al., 1982), and other workers have
found differences between American and European ILTV strains
and between an American field strain and a vaccine strain
(Leib,  et al., 1986).  Differences in DNA patterns between
live ILTV vaccines, reference strains of ILTV, and ILTV field
isolates from North Carolina have also been studied by using
restriction endonucleases (Guy, et al., 1989).  Differences
between DNA patterns of vaccine strains and Georgia field6 
isolates of ILTV were also found (Andreasen, et al., 1990).
Differences among restriction endonuclease DNA fingerprints
of Pennsylvania field isolates, vaccine strains, and challenge
strains of ILTV have also been reported  (Keller,  et al.,
1992).  The use of cloned DNA fragments in reciprocal DNA:DNA
hybridization also appears promising for differentiating ILTV
strains (Kotiw, et al., 1986).
Monoclonal antibodies can be used to study the antigenic
relationship among virus isolates and other isolates of the
same  family.  Work has  been done  to  observe antigenic
relationship in paramyxoviruses, and different strains have
been classified by using monoclonal antibodies in reactions
such as the indirect immunoperoxidase test, haemagglutination
inhibition  test,  and  the  binding pattern  of monoclonal
antibodies with the infected cells (Alexander, et al., 1989;
Collins,  et al.,  1989).  Monoclonal antibodies potentially
could be used to distinguish strains of ILTV.
Laboratory Host System
Infectious laryngotracheitis virus can be propagated in
embryonating chicken eggs.  The virus causes formation of
opaque  plaques  on  the  chorio-allantoic  membrane  (CAM)
resulting from proliferative and necrotic lesions.  Embryo
deaths occur in 2-12 days postinoculation (Brandly,  1935;
Brandly, 1937).
Infectious laryngotrachetis virus can also be grown in
chicken embryonic liver (CEL), chicken embryo kidney (CEK),7 
and chicken kidney (CK) cell cultures (Atherton & Anderson,
1957).  Chicken embryonic liver and CK are the preferred
culture systems (Hughes & Jones, 1988).
The virus can also grow in cultures of cells from  the avian
immune system, but only to extremely low titers.  Chicken
leukocytes (buffy  coat) can also be used in vitro for viral
growth (Chang, et al., 1977).  Viral growth at low titer has
been observed in macrophages cultured from bone marrow and
spleen (Bulow & Klasen, 1983).  Susceptibility of macrophages
in vitro does not correlate with susceptibility of infection
with ILTV (Louduvaris, et al., 1991).
Genome of ILTV
A comparative study of DNA density and behavior in tissue
culture of 14 different herpesviruses  found that the nucleic
acid core of ILTV is DNA, with a density of 1.704 g/ml, which
is  consistent  with  DNA  values  of  some  of  the  other
herpesviruses (Plummer, et al.,  1969).  A molecular weight
estimation of ILTV DNA was made by summation of restriction
endonuclease fragments cleaved with Bam HI (102.1 x 106) and
Hind III (97.35 x 106).  Difference between the estimates may
indicate the presence of submolar fragments.  These findings
indicate  that  the  molecular  weight  of  ILTV  DNA  is
approximately 100 x 106, with the genome having two isomeric
forms (Kotiw, et al., 1982).  Other workers also investigated
genome isomerism of ILTV  using restriction endonuclease
analysis, and ILTV DNA was found to have two isomers with a8 
molecular weight of 109 x 106 (Leib, et al., 1986).  Clones of
ILTV have been used in hybridization experiments by workers
and it was found that the genome is 155 kilobase pairs (Kbp)
and is comprised of a long unique sequence of 120 Kbp and a
short unique sequence of 17 Kbp bounded by repeat sequences
each of 9 Kbp.  They also found an unrelated second pair of
repeat sequences located at  0.67 and 0.88 map units.  A
terminal repeat of the unique long region was also detected,
but no isomerization of the unique long sequence was found
(Johnson, et al., 1991).  Infectious laryngotracheitis virus
DNA has been reported  to have  a  guanine plus  cytosine
percentage of 45% (Plummer, et al., 1969), which is lower than
that for many other animal herpesviruses.  Some workers have
studied the nucleotide sequence of the ILTV gene coding the
205K complex glycoprotein (gb 205) and have found that the
gene is contained within a 3 kb EcoRI restriction fragment
mapping at map coordinates 0.23 to 0.25 in the unique long
region of the ILTV genome and is transcribed from right to
left (Kongsuwan, et al., 1991).
ILTV Proteins and Glycoproteins
Four major glycoproteins of molecular weights 205,  115,
90, and 60 Kd, respectively, have been located both on the
virus and the surface of virus-infected cells (York, et al.,
1987), and are considered to be the major immunogens of ILTV.
Monoclonal antibodies (MCAs) to immunogenic glycoproteins were
produced and characterized by immunoprecipitation and western9 
blotting.  One group of MCA reacted only with the 60 Kd
glycoprotein, by both techniques, while a second group reacted
with  the  205,  115,  and  90  KD  glycoproteins  in
immunoprecipitation and with additional bands of 85 and 160 KD
in Western blotting (York,et al.,1987).  Glycoproteins
with molecular weights less than 60 Kd have been detected in
extracts of virus-infected cells.
In a recent study,  the glycoprotein B  (gB)  gene was
identified using the polymerase chain reaction. Northern blot
analysis using a portion of open reading frame as a probe
identified a 2.7 kb RNA transcript in ILTV-infected chicken
embryo liver cells, and analysis of the amino acid sequence of
the ILTV protein indicated that it shares structural features
with the gB glycoproteins of other herpeseviruses (Poulsen, et
al., 1991).
Pathogenesis
The chicken is the primary natural host affected by ILTV,
but several workers have described a form of ILT in pheasants
and pheasant-chicken crosses  (Kernohan,  1931;  Crawshaw &
Boycott, 1982).  Lesions were experimentally induced in the
upper respiratory tract of young turkeys (Winterfield & So,
1968).  Starlings, crows, doves, ducks, pigeons, and guinea
fowl are not susceptible to ILTV  (Beach,  1931; Brandly &
Bushnell, 1934), although experimental infection of ducks has
been reported (Yamada, et al., 1980).
Natural  infections  by  ILTV  occur  through  upper10 
respiratory and ocular routes  (Beaudette,  1930; Beaudette,
1937).  Ingestion  can  also produce  infection,  although
exposure of nasal epithelium following ingestion is required
with this route (Robertson & Egerton, 1981).  Transmission
occurs more readily from acutely infected birds than through
contact with clinically recovered carrier birds.
Viral replication is  limited to upper respiratory tract
tissues,  with little or no evidence of viremia normally
occurring (Bagust,  et al., 1986;  Hitchner, et al., 1958).
Affected tracheal mucosa becomes  swollen  and  edematous,
resulting  in  erosion  and  hemorrhage.  Infectious
laryngotracheitis virus  is  usually present  in tracheal
tissues and secretions for only 6-8 days postinoculation
(Bagust, et al.,  1986; Hitchner, et al.,  1977; Robertson &
Egerton, 1981).  Mechanical transmission can occur by use of
contaminated equipment and litter (Kingsbury & Jungherr, 1958;
Dobson, 1935; Beaudette, 1937).  Egg transmission of virus has
not been demonstrated, and ILTV infected embryos die before
hatching (Jordan, 1966).
A recent study suggests a possible  association  of the
chicken  major  histocompatibility  complex  (MHC)  with
susceptibility and resistance of chickens to ILTV (Loudovaris,
et al., 1991).
Characteristic signs of an acute infection are nasal
discharge, and moist rales followed by coughing and gasping
(Beach, 1926; Kernohan, 1931).  In severe forms of the disease11 
there is severe dyspnea and expectoration of blood-stained
mucus  (Beach,  1926;  Hinshaw,et al.,  1931;  Seddon & Hart,
1935).  Mild enzootic forms of the disease have been described
in Britain, Australia,  the United States, and New Zealand
(Cover & Benton, 1958; Pulsford & Stokes, 1953; Seddon & Hart,
1935). In mild forms, signs are unthriftiness, reduction in
egg production,  watery eyes,  conjunctivitis,  swelling of
infraorbital  sinuses,  persistent  nasal  discharge,  and
hemorrhagic conjunctivitis (Seddon & Hart, 1935; Pulsford &
Stokes, 1953; Cover & Benton, 1958).  Most chickens recover in
10-14 days, but extremes of 1-4 weeks have also been reported
(Hinshaw, et al., 1931; Beach, 1926). Reactivation of latent
ILTV has not been achieved by using immunosuppressive drugs
(Hughes, et al., 1987., Bagust, 1984).
The incubation period is 6-12 days following natural
exposure (Kernohan, 1931; Seddon & Hart, 1935).  Intratracheal
exposure results in a shorter incubation period of 2-4 days
(Seddon & Hart, 1935; Benton, et al., 1958). Mortality varies
from 5-70% (average 10-20%) in epizootic form of the disease,
which spreads rapidly in susceptible chickens (Beach, 1931;
Hinshaw, et al., 1931; Seddon & Hart, 1935).  In the benign
forms  of  the disease seen  in recent years  in  the USA,
Australia, and the UK, morbidity is low and mortality varies
from 0.1-2% (Curtis & Wallis, 1983; Davidson & Miller, 1988).
Immunity
Chickens  gain  resistance after being  infected;  the12 
duration of  resistance induced from a  natural  infection
appears to be a year or more.  Immunity induced by vaccination
is of variable duration.  Cell-associated (chicken embryo
fibroblast cells) vaccine prepared from an attenuated ILTV
provides adequate protection when given at  1  day of age
intramuscularly or subcutaneously, and the chickens acquire
immunity within 6 days after vaccination.  The protection rate
remains above 60% until 10 weeks post-vaccination (Taneno, et
al.,  1991).  Infectious laryngotracheitis virus infection
causes the production of antibodies that can neutralize virus
(Bagust, et al., 1986).  The humoral response associated with
infection is not a primary mechanism of protection against
ILTV infection.  There is a poor correlation  between serum
antibody titers and the immune status of a flock (Jordan,
1981)  Resistance to ILTV due to cell-mediated responses is of .
greater importance.  Bursectomized chickens, which can not
produce a humoral response, can develop immunity following ILT
vaccination (Robertson,  1977).  Some workers have reported
transmission of maternal antibodies to ILTV through the egg to
the offspring (Benton, et al., 1960).  The antibody does not
interfere with vaccination,  and does not provide a long-
lasting protection.  Older birds respond well to vaccination
as compared to  chickens less than two weeks of age (Alls, et
al.,  1969; Cover, et al., 1960; Gelenczei & Marty, 1965),
although chickens can be successfully vaccinated as early as
1 day old (Sincovic & Hunt, 1968).13 
Diagnosis
Although  some  acute  signs  of  the  disease  are
characteristic, signs are often similar to other respiratory
diseases, so ILT can not be reliably diagnosed by observation
of signs and lesions. Laboratory confirmation is required for
certain diagnosis.
Virus can be isolated from tracheal and lung tissue by
chicken embryo inoculation, by inoculation of trachea, and
infraorbital  sinuses  of  susceptible chickens  (Hitchner  &
White, 1958), or by cell culture inoculation (Chomiac, et al.,
1960).  Inoculation of ILTV is achieved by inoculation of
suspension from tracheal exudate, tracheal tissue, or lung
tissue onto the CAM of 9-12 day old embryonated egg or into
susceptible cell culture.  Cytopathic effect  (CPE)  can be
observed 24-48 hours later (Hitchner & White, 1958).  Chicken
embryo liver cells and chicken kidney cells are the laboratory
systems of choice for the isolation of ILTV (Hughes & Jones,
1988).
Demonstration  of  intranuclear  inclusion  bodies  in
tracheal and conjunctival tissues stained with Giemsa stain is
also diagnostic of ILTV (Cover & Benton, 1958; Beveridge &
Burnet,  1946).  Intratracheal  inoculation with  tracheal
exudate or tissue suspension from recently affected birds can
provide a reliable diagnostic procedure (Pulsford & Stokes,
1953).  Electron microscopic  (EM)  examination of tracheal
scrapings and recognition of herpes virus particles is also a14 
way of rapid diagnosis (Van Kammen & Spradbrow, 1976).  The
fluorescent antibody test may also be used for identification
of  virus  (Braune  &  Gentry,  1965).  Infectious
laryngotracheitis virus was detected in tracheal tissue from
day 2  to day 14 postinoculation using  fluorescein-labelled
anti-LTV globulins (Bagust, et al., 1986; Hitchner, et al.,
1977; Wilks & Kogan,  1979).  Recently, an enzyme-linked
immuno-sorbent assay (ELISA) using monoclonal antibodies was
developed for rapid detection of ILTV antigen in tracheal
exudate  (Van Kammen & Spradbrow,  1976).  Enzyme-linked
immun-osorbent assay systems for detection of ILT antibodies
have also been developed (Ohkubo, et al., 1988; York & Fahey,
1988; York, et al., 1983). Virus neutralization (VN) can be
measured by using the CAM-pock counting technique, and VN
antibodies can also be detected in cell culture  monolayers
(Robertson & Egerton, 1977; Churchill, 1965).
Infectious laryngotracheitis virus DNA was also detected
in tracheal samples in a DNA hybridization assay by using a
non-radioactive probe, and this technique has been found very
effective in detecting field outbreaks and also latent ILTV
infections (Keam, et al., 1991).
Infectious laryngotracheitis virus antigen has also been
in  frozen  tissue  section  by  an  indirect detected
immunoperoxidase (IP) procedure using monoclonal antibodies
(Guy, et al., 1992).15 
Treatment, Prevention and Control
No drug has yet been found effective in reducing the
severity of ILT.  Vaccination of chickens for ILT has proven
to induce adequate protection.  Live attenuated vaccines which
are given in drinking water and by eye drops are very
effective against ILT.  Mild field isolate SA-2, which has
been used for vaccination in Australia, is able to establish
latent  infections  (Bagust,  1986).  Cell-mediated  immune
responses are thought  to be protective against infection
after  vaccination.  Bursectomized  chickens  were  found
resistant  against  a  challenge  infection,  while  passive
transfer of hyperimmune serum failed to protect against the
infection (Fahey, et al., 1983).  Infectious laryngotracheitis
virus attenuated by passage in cell cultures (Izuchi, et al.,
1984;  Izuchi,  et al.,  1983; Gelenczei & Marty,  1964),  or
embryonated eggs, and selected mild enzootic strains (Pulsford
& Stokes, 1953) are capable of inducing acceptable protection
and are used in vaccines.  Virulent strains of ILT vaccine
should be administered with caution, because vaccination may
result in some carrier birds.  Inoculation of infraorbital
sinuses  (Shibley,  et  al.,  1962),  intranasal  installation
(Benton, et al., 1958), feather follicle inoculation (Molgard
& Cavett, 1947), eye drop (Sinkovic & Hunt, 1968), and oral
administration through drinking water (Hilbink, et al., 1981)
have been used to vaccinate chickens against ILTV.  Most layer
or breeder chickens are now vaccinated by the eye drop method16 
using attenuated ILTV vaccine.  When broiler vaccination is
required, spray or drinking water application is usually used.
Successful vaccination through the drinking water depends upon
ILTV contacting the epithelium of the nasal cavity during
drinking.
Glycoproteins of ILTV, purified from detergent extracts of
virus-infected cells by lectin affinity chromatography, have
also been used for vaccination of chickens, and have been
proven to protect up to 83% of chickens against ILTV.  Both
neutralizing  antibody  and  delayed-type  hypersensitivity
responses were  induced by vaccination with glycoprotein
preparation, but neither correlated with protection (York and
Fahey, 1991).
Proper management procedures help prevent the disease,
including sound sanitation and hygiene measures, control of
movement of staff, service workers, feed, equipment and birds,
as well as rodent and dog control measures (Kingsbury, et al.,
1958).
A resolution pertaining to the proposed eradication
program for ILT was unanimously passed by a United States
Animal  Health Association  committee.  The  proposed  ILT
eradication program  consists of four phases  (Proc. USAHA;
1990).  These four phases cover all aspects of a complete
eradication  program,  including  diagnostic  capabilities,
vaccination, surveillance,  biosecurity, and treatment of the
infected flocks and infected houses.17 
Monoclonal Antibodies
Monoclonal antibodies are a homogenous population of
identical antibodies with a defined specificity secreted by a
B-cell clone after fusion with tumor cells.  Monoclonal
antibodies (MCAs) do not differ structurally from naturally-
occurring polyclonal antibodies.  The property which makes
MCAs  unique  is  that  all  the  molecules  in  any  single
preparation are identical.  Monoclonal antibodies have same
specificity of reaction with any defined antigen every time
when ever reacted.
Since  1975  MCAs  have been  considered  an  important
discovery in the field of science.  On August 7, 1975, Kohler
and  Milstein  published  in  Nature  a  report  describing
"continuous cultures of fused cells secreting antibody of
predefined specificity" (Kohler & Milstein, 1975).  The first
workshop on lymphocyte hybridomas was held on April 3-5, 1978,
in Bethesda, Maryland.  Kohler and Milstein (1975) observed
that somatic cell hybridization could be used to generate a
continuous  "hybridoma"  cell  line producing  a  monoclonal
antibody.  Immunologists have since produced large amounts of
homogenous  monoclonal antibodies against a wide variety of
antigens.
Monoclonal  antibodies  have  been  produced  against
histocompatibility,  differentiation,  tumor or other cell-
surface antigens, as well as viral and bacterial antigens and
certain single antigenic determinants on a wide variety of18 
proteins, nucleic acids, and sugars. Monoclonal antibodies to
certain specific antigens are available commercially.
The primary advantage of MCAs as diagnostic reagents is
their specificity of binding to a single epitope, producing
highly  specific  diagnostic  test  reagents.  Monoclonal
antibodies are used for many research purposes.  Examples
include construction of antigenic maps of the haemagglutin
molecule of influenza virus, in vitro estimation  of mutation
rate or genetic changes of influenza virus by culturing virus
in presence of a single neutralizing monoclonal antibody, use
of  monoclonal  antibodies  in  passive  protection  against
different antigenic determinants of  influenza virus,  and
ability  of  monoclonal  antibodies  to  separate  individual
antigens from a complex mixture (Antczak, 1982; Re, 1987).
For production of MABs, a suitable host is  immunized
with an antigen.  Antibody-secreting B cells are obtained from
the spleen of the immunized host and fused with myeloma cells
in medium containing hypoxanthine, aminopterin, thymidine (HAT
medium).  Normal cells have two pathways  for nucleotide
synthesis, de novo pathway and salvage pathway. Myeloma cells
do not have hypoxanthine-guanine phosphoribosyl transferase
(HGPRT)  which is responsible for the salvage pathway,  so
because of the absence of this enzyme they are sensitive to
aminopterin, which inhibits dihydrofolate reductase and hence
blocks de novo purine and thymidilate synthesis.  Fused cells
are  thrown  in  the  salvage pathway,  being provided with19 
hypoxanthine and thymidine in the medium.  Fused cells have
HGPRT which utilizes the hypoxanthine for purine synthesis and
also have thymidine kinase which utilizes the thymidine for
thymidylate synthesis.  Both of these enzymes are provided by
the spleen cells after fusion.  Unfused B cells die naturally
in the media because they are not immortal like myeloma cells.
Because of the effect of aminopterin, unfused myeloma cells
will be killed too.  Only  fused cells can survive in this HAT
medium because of HGPRT and thymidine kinase provided by the
B cells, which is responsible for the salvage pathway, and
immortalization provided by the myeloma cells.  Positive
hybridomas producing the desired antibody are identified, and
cloning is done to get specific monoclonal antibodies (Goding,
1986; Harlow & Lane,  1988).  Enzyme-linked immuno-sorbent
assay and indirect immunofluorescence tests are most commonly
used for identification of positive hybridomas.  There are
different ways of cloning, but a common way is cloning by
limiting dilution at the rate of <1 cell/well.
Four animal species can be used for MCA production:
mouse, rat, hamster, and rabbit.  Rabbit MCAs have recently
been described (Raybould & Takahashi, 1988).  Mice are the
best choice for immunization and production of MCAs because
mice  are  easier  to  handle  and  there  are  many  anti
immunoglobulin (Ig) reagents available that are specific for
each mouse Ig isotype.  Also, mouse MCAs are easier to purify
than rat.20 
Female BALB/c mice are preferred  if  the  SP2/0-Ag14
myeloma cell line is used as a fusion partner because the
hybridomas resulting from this fusion will be entirely of
BALB/c origin.  Such hybridomas can grow well in BALB/c hosts
for the production of ascites fluid.  The sex of the mice does
not matter except that females are easier to handle and are
less agressive.21 
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CHAPTER II
PRODUCTION OF MONOCLONAL ANTIBODIES AGAINST THE USDA
CHALLENGE STRAIN OF INFECTIOUS LARYNGOTRACHEITIS VIRUS31 
Introduction
Infectious laryngotracheitis virus (ILTV) is assigned to
the subfamily Alphaherpesvirinae, of the Herpesviridae family
on the basis of its rapid replication and latency in neurons.
It is an enveloped virus, icosahedral, with double stranded
DNA which has a density of 1.704 g/ml, similar to the DNA of
other herpes viruses  (Plummer,  et al.,  1969).  Four major
glycoproteins with molecular weights 205, 115, 90, and 60 kD
have been described in the SA-2 strain of ILTV (York, et al.,
1987).  These glycoproteins are considered to be the  major
immunogens of ILTV and are present on the virus envelope and
on  the  surface  of  virus-infected  cells.  Infectious
laryngotracheitis virus DNA has a molecular weight of about
100 x 106, with the genome having two isomeric forms (Kotiw,
et al., 1982; Leib, et al., 1987).  Some workers have reported
that ILTV has a guanine plus cytosine percentage of 45% which
is lower than other animal herpesviruses (Plummer,  et al.,
1969).
The envelope  glycoproteins are important immunogens
capable of inducing humoral and probably cellular immune
responses.  The involvement of other virion components in
inducing immune responses has not been investigated  (Watari,
et al., 1987).
Chicken antisera and rabbit antisera have been used to
immunoprecipitate four major glycoproteins of 205, 115,  90,
and 60kD molecular weight.  Some additional glycoproteins also32 
have been recognized by immune chicken and rabbit antisera in
western blotting using a glycoprotein fraction which was
purified from virus-infected cells (York, et al., 1987).  The
same workers have also produced monoclonal antibodies (MCAs)
and have  characterized them by immunoprecipitation and
western blotting. They have defined 5 groups of MCAs. Group 1
reacted with the 60kD by both techniques, and group 2 MCAs
reacted with  the  205,  115,  and  90kD  glycoproteins  in
immunoprecipitation. The reactivity of group 1 and group 2
MCAs in immunofluorescence suggests that the antigens are
present on the surface  of virus infected cells. Group 2
antibodies recognized at  least three epitopes,  which was
confirmed by ELISA additivity assays.  Group 3,  4,  and 5
antibodies recognized several proteins with lower molecular
weights from 45  to 24kD.  Furthermore,  on the basis of
immunofluorescence studies,  it was found that the antigens
recognized by groups 3, 4, and 5  were nuclear and cytoplasmic
antigens  that were not present on the surface of virus
infected  cells (York,  et al., 1990).
All strains of ILT virus isolated throughout the world so
far are antigenically  homogenous on the basis of  their
reactions in virus neutralization tests. However, restriction
endonucleases have been used to study the DNA patterns and
some workers have found differences among some strains of ILTV
(Kotiw, et al., 1982; Leib, et al., 1986).
Once monoclonal antibodies are produced, they can be used33 
in  various  diagnostic  tests  such  as  the  indirect
immunofluorescent antibody test (IFAT), virus neutralization
(VN), enzyme  linked immunosorbent assay (ELISA), etc.  Virus
neutralization activity has been assayed by some workers using
the plaque reduction method  (York, et al., 1989).  There are
various techniques to characterize these antibodies such as
western blotting, immunoprecipitation test, IFAT, ELISA.
The objective  of the present research was to produce
monoclonal antibodies against the USDA challenge strain of
infectious laryngotracheitis virus and to perform an initial
investigation of their use in an indirect immunofluorescence
diagnostic test.
Materials and Methods
Source of Virus:  Infectious laryngotrachetis virus
strains include the United States Department of Agriculture
(USDA) challenge strain, provided by the National Veterinary
Services Laboratory in Ames, Iowa; 86-1169, a Georgia field
isolate; and S 88 00224, a California field isolate.  Other
viruses including a parrot herpesvirus  (Pacheco's disease
virus) and avian adenovirus 301, were obtained from The Avian
Serology Laboratory, Veterinary Diagnostic Laboratory, Oregon
State University.  The parrot herpesvirus was isolated in
chicken embryo liver cells from the liver of a parrot that
died acutely.
Virus Growth and Purification:  Chicken embryo liver
cells were made from 14-day old chicken embryos.  The livers34 
were removed aseptically and placed  in phosphate-buffered
saline (PBS)  (0.16% sodium phosphate dibasic, 0.05% potassium
phosphate monobasic, and 0.73% sodium chloride; pH 7.2) in a
beaker.  Calcium and magnesium free PBS was used. After
chopping  with  scissors, livers were washed 5-6 times with
PBS to eliminate the red blood cells (RBCs) and other fibrous
tissue.  Versene-trypsin (Sigma, St. Louis, MO 63178 USA;
Trypsin 20 mg/ml, Versene 2 mg/ml)  was used to separate the
cells.  Trypsinization was  stopped by adding sufficient
chilled  fetal  bovine  serum  (FBS)  to  produce  an  8%
concentration, and cells were centrifuged at 750 X g for 5
minutes.  Packed  cells  were diluted at the rate of 1:150 in
minimal essential medium (MEM)  (Sigma, M0643) containing 10%
FBS, gentamicin (50 ug/ml), and Amphotericin-B (2.5ug /ml)  (pH
7.0-7.1).
Five ml of diluted cells were added to 60-mm tissue
culture plates and were kept in a 5% CO2 incubator at 37C
overnight until a liver cell monolayer formed.  Each tissue
culture plate with a grown monolayer was infected with 0.1 ml
of 1:10 dilution of ILT cell culture supernatant.  After
infection, cells were incubated 1 hour at 37C in a  5% CO2
atmosphere to allow  virus adsorption.  Infected plates were
fed with growth medium containing 4% FBS and incubated at 37C
and 5% CO2 for 24 hours.  Only the cells which were infected
with the USDA challenge strain of ILTV were used for the
purification of virus for monoclonal antibody production.35 
Other viruses including Parrot herpesvirus, and adenovirus 301
were also used to infect the cells for certain comparative
studies.
Cells having a good growth of virus,  as determind by
extensive cytopathic effect  (CPE)  characteristic of ILTV,
were washed with TEN buffer  (0.01 M tris, 0.001 M EDTA, 0.1
M sodium chloride in distilled water)  (pH 7.2).  Cells were
scraped from the tissue culture plates and collected in a 50
ml tube.  Virus particles were released by sonification and
the solution was  centrifuged at 5930 X g for 25 minutes to
separate the cellular debris.  The supernatant  (32 ml) was
retained,  and 16 ml of the supernatant was layered onto
discontinuous sucrose gradients in centrifuge tubes containing
8  ml  65%  (w/w)  sucrose under  10  ml  30%  (w/w)  sucrose.
Supernatant was centrifuged through this discontinuous sucrose
gradient at  100,000 X g for 1 hour.  Visible virus bands were
collected (15 ml) from the 30%-65% sucrose interface.  Two ml
of this fluid was added to the top of each tube  (6 tubes)
containing continuous  sucrose gradients.  The continuous
sucrose gradient was made from four different concentrations
of sucrose in the same tube: 60% sucrose  (w/w) was at the
bottom of the tube under 50%,  40%,  and 30% sucrose  (w/w)
respectively.  Virus was  centrifuged through the gradient at
100,000 X g  for 19 hours.  Visible virus bands were collected
(15 ml).  The refractory index of the virus-sucrose solution
was 1.410 and the density was  1.20 g/cm3­36 
After diluting the virus and sucrose in 15 ml TEN buffer,
the solution was placed in a concentrator  (100,000 MW )
(Amicon, Beverly MA 01915 USA) and centrifuged  at  1250 X g
for 45 minutes.  This centrifugation process was repeated 3
times to eliminate  sucrose.  Dialysis was performed by
keeping dialysis tubing containing virus-sucrose solution in
TEN buffer for 48 hours to completely eliminate sucrose.  The
dialysis tube has a semi-permeable membrane which allows only
sucrose and TEN buffer to pass through the membrane.  Dialysis
was  followed  by  another  three  centrifugations  in  a
concentrator.  Five ml of purified ILTV was obtained.
Virus particles  were seen in the solution by electron
microscopy.  Spectrophotometry was used to measure protein
concentration as 68.117 ug/ml and nucleic acid concentration
as 9.8948 ug/ml.  Purified virus was stored at -70C.
Mouse Immunization:  Purified  virus was thawed in a
water bath at 37 C, and 0.8 ml of virus was mixed with 0.8 ml
of Freund's complete adjuvant (Sigma) by sonification.  Five
10-week-old  female  BALB/c  mice  were  immunized
intraperitoneally  (IP)  with 0.2 ml of emulsion containing
virus and Freund's complete adjuvant.  The mice were marked by
ear punch for individual identification.  Three weeks later a
second injection (0.2 ml, IP) of ILTV antigen, consisting of
incomplete Freund's adjuvant mixed in equal amount with the
purified  virus was given to all 5 mice.
Three weeks after the first injection of antigen, blood37 
was obtained from the conjunctival venous sinus of each mouse
using 100 ul heparinized capillary tubes.  Serum was separated
by centrifugation.  Serum 1:100 dilution was checked for
antibody against ILTV  by the indirect immunofluorescence
test.  Subsequently serum was checked every week for antibody
against ILTV until fusion.  Mice 1,  3,  and 5  continued to
respond best.  Four weeks after the first injection a third
injection (0.2 ml, IP) of ILTV in incomplete Freund's adjuvant
was given to all 5 mice.  An intravenous booster injection of
the purified virus without any adjuvant was given to mice 1,
3, and 5 four days before fusion, that is 8 weeks after the
first injection.  Five female BALB/c mice of the same age and
sex were kept as unimmunized control mice for a source of
negative control sera.  Serum from mice responding to the
viral antigen was also collected for use as positive control
serum before mice were sacrificed.
Fusion and Cloning:  SP2/0-Ag14 myeloma cells were fused
with spleen  cells  of  the mice  immunized with the USDA
challenge  strain  of  ILTV  for  production  of  monoclonal
antibodies  (Kohler & Milstein,  1975;  Current Protocol in
Immunology, 1991).  One day before fusion, feeder plates were
made from spleen cells of a female BALE /c mouse that had not
experienced any antigen exposure.  Mice were killed by
dislocating the cervical vertebrae and disinfected with 70%
alcohol before placing them in a sterile cabinet.
Spleens  from  three  immunized  mice  were  removed38 
aseptically, minced, and washed twice in complete Dulbecco's
Modified  Eagle's  medium  (DMEM)  (Sigma)  without  serum,
containing 1 ml penicillin/streptomycin (100X) in 100 ml of
DMEM,  1 ml of L- glutamine (100X)  in 100 ml of DMEM.  The
medium (DMEM)  was prepared according to supplier's directions
(Sigma,  pH  7.2).  The  medium  was  filtered  and  kept
refrigerated.  Spleen cells were mixed by repeatedly and
gently pipetting them with the media.  The spleen cells were
centrifuged at 750 X g for 5 minutes.  Cells were counted with
a hemocytometer.  The spleen cells were mixed with SP2/0-AG 14
mouse myeloma cells at the ratio of 1:1 (Schulman, et al.,
1978).  The combined cells were centrifuged at 750 X g for 5
minutes,  the supernatant was discarded,  and  1  ml  of  50%
polyethylene glycol (PEG)  (Sigma) was added to the cells as a
fusion reagent  (Poste & Allison,  1973).  Cells were mixed
very slowly in 2 ml of serum free DMEM and then in 7 ml of
serum free DMEM by stirring the cells very gently  with the
pipet.  Cells  were  centrifuged  and  resuspended  in
hypoxanthine  aminopterin  thymidine  (HAT)  (Sigma)  media
containing 20% FBS, HAT (5 x 10-3 M hypoxanthine,  2 x 10-5 M
aminopterin,  8  x  10-4  M thymidine),  pen/strep  (10,000  u
penicillin/ml, 10 mg streptomycin/ml), L-glutamine (200mM),
hepes  buffer  (Sigma)  (1  M),  and  OPI  (Sigma)  (0.15  g
oxaloacetate, 0.5 g pyruvate, and 0.0082 g bovine insulin per
10 ml).
One hundred ul of cell suspension was added to each well39 
of 96 well tissue culture plates (feeder plates) and incubated
at 37C in a  5% CO2 atmosphere.  Cells were fed  every 2 days.
For the first feeding,  the wells were fed with the media
containing HAT,  while for the second feeding hypoxanthine
thymidine media (HT media) was used.  After that, wells were
fed with complete DMEM containing 10% serum.  Screening
normally begins 10-14 days after fusion.  Supernatant fluids
from wells were screened by IFAT for specific ILTV antibodies
when the culture supernatant became acidic (yellowish) and the
hybridomas were grown enough to produce specific antibodies.
The hybridomas grow in the form of a clump of cells which is
visible using a microscope.  The hybridomas that were found to
be producing antibodies were cloned by limiting dilution
calculated to give <1 cell/well.  Ten cells per ml were
calculated by serial dilution and were plated onto feeder
plates at the rate of 100 ul/well to give <1 cell/well.
Cloning was done twice.
Fusion was done according the procedure given in Current
Protocols in Immunology, Green Publishing Associates and Jhon
Wiley and Sons, 1991., with slight modeficaton.
Production of Cloned Antibodies:  Monoclonal antibodies
were produced by growing cloned hybridomas in 80 cm'  tissue
culture flasks in complete DMEM containing 10% FCS.  Extinct
cultures of the cells were made by incubating the cells at 37C
in a 5% CO2atmosphere for 20 days without providing any media
after the cells were sufficiently grown.  This gave a very40 
high titre of antibody in the cell supernatent.  After 20 days
the cells were centrifuged and the supernatant was collected
in small aliquots and stored at -20C.
Screening  By Using  Indirect  Immunofluorescence  Test
(IFAT):  Infectious laryngotrachetis virus infected cells and
uninfected cells were collected from tissue culture flasks.
The cells were washed with PBS, and were centrifuged at 450 X
g.  The supernatant was discarded and the cell pellet was
suspended in 0.01M FA buffer (containing Na2HPO4, NaH2PO4.H20,
and NaCl) with 2% bovine serum albumin (BSA) and centrifuged
as before.  The supernatant was discarded and the cell pellet
was  resuspended  in  FA buffer  containing  2%  BSA.  One
microliter  of the ILTV-infected cells was smeared on each
top-row well of teflon-coated slides  (Cel-line Associates,
Inc.  P.O. Box 35. Newfield, NJ 08344).  Slides for other
virus-infected cells such as ILTV S 88 00224, ILTV 86-1169,
adenovirus 301, and parrot herpes virus were made in the same
way.  Uninfected cells were smeared on the wells on the bottom
row of the slide to serve as negative cell controls.  All
slides  were  fixed  in  acetone  for  10  minutes.  Twenty
microliters of undiluted hybridoma supernatant was added to
infected and uninfected wells. Negative control sera  (1:5
dilution) and positive control sera (1:100 dilution) were also
used at the time of screening of hybridomas for comparison.
After putting hybridoma  supernatant  or  control  sera  on
infected and uninfected cells, the slides were incubated for41 
20 minutes at 37C in a 5% CO2  atmosphere.  Slides were washed
with FA buffer and were soaked in FA buffer for 20 minutes.
Slides were washed with double distilled water, rinsed, and
air dried completely.  Twenty microliters of rabbit anti-mouse
immunoglobulin (Sigma; Jackson Immunoresearch Laboratories,
Inc,  872 Baltimore Pike,  PO Box 9,  West Grove,  PA 19390)
(1:200  dilution)  was added to each well of infected and
uninfected cells and incubated for 20 minutes.  Slides were
washed with FA buffer and soaked in FA buffer for 20 minutes.
Slides were washed with double distilled water, rinsed, and
counterstained for 5 minutes with 0.0001% Evan's blue.  Slides
were  air  dried,  mounted  with  mounting  fluid  (Difco
Laboratories, Detroit, Michigan USA) having a pH of 9.0, and
were examined under a fluorescent microscope.
Immunoqlobulin Subclass:  The isotypes of the monoclonal
antibodies were determined by a mouse monoclonal antibody
isotyping kit  (Sigma)  containing rabbit anti-mouse  IgG1,
IgG2a,  IgG2b,  IgG3,  IgM,  and IgA following manufacturer's
procedures.  The immunotype kit consists of nitrocellulose
strips on which the entire assay is completed.  The precoated
strip captures the relevant mouse immunoglobulin and reveals
the  isotype by self-description.42 
RESULTS
Monoclonal Antibodies.  Of 234 growing hybridomas,  15
showed positive reactions with cells infected with ILTV USDA
challenge strain and no reaction with uninfected control
cells.  Five of the 15 died during the process of expansion
and cloning.  Four of the remaining 10 proved to give negative
reactions, and 3 reacted both with infected and non-infected
cells on the second screening after cloning by limiting
dilution.  Three hybridomas were found positive against the
USDA challenge strain of ILTV and were designated as 2D1D8,
2E11G2, 2C6C7.
Isotypic  Characterization.  Monoclonal  antibodies
secreted by the three hybridomas were isotyped using the
isotyping kit, and all three hybridomas 2D1D8, 2E11G2, and
2C6C7 were found to secrete IgM (Table 1).
Indirect Immunofluorescence Assay.  All three monoclonal
antibodies  2D1D8,  2E11G2,  2C6C7  reacted in  an  identical
manner, fluorescence being found mainly along the peripheries
of  the infected cells.  Monoclonal antibodies were also
examined against other viruses including S 88 00224 isolate of
ILTV, 86-1169 isolate of ILTV, a parrot herpesvirus, and avian
adenovirus 301  (Table 2).  The other two strains of ILTV
reacted in the same manner as the  USDA challenge strain of
ILTV against all three monoclonal antibodies.  Fluorescence
was observed mostly at the peripheries of the infected cells
(Fig.1).  Cells infected with parrot herpesevirus and avian43 
adenovirus 301 did not produce any fluorescence with any of
the monoclonal antibodies.
The reaction of all three monoclonal antibodies with the
different isolates of ILTV and production of fluorescence was
almost identical. This suggests that the other isolates of
ILTV share the same antigen and the same epitope as the USDA
challenge strain of ILTV.44 
Table 1.  Isotypes of monoclonal antibodies secreted by the
three cloned hybridomas producing ILTV-specific antibodies.
Isotypes  Monoclonal antibody supernatants
2D1D8  2E11G2  2C6C7
IgM  + 
IgG1 
IgG2a 
IgG2b 
IgG3 
IgA 45 
Table 2.  Reaction of monoclonal antibodies with different
strains of ILTV and some other viruses as determined by
indirect immunofluorescence.
Virus  Strain  Monoclonal antibody supernatant
2D1D8  2E11G2  2C6C7
ILTV USDA  +  +  +
ILTV  S 88 00224  +  +  +
ILTV  86-1169  +  +  +
Avian Adenovirus 301
Parrot herpes virus46 
Figure  1.  Indirect immunofluorescence staining of cells
infected  with  USDA  challenge  strain  of  infectious
laryngotracheitis virus with 2D1D8 monoclonal antibody.47 
Figure  2.  Indirect immunofluorescence staining of cells
infected with avian adenovirus 301 with 2D1D8 monoclonal
antibody.48 
Discussion
Three monoclonal antibodies designated 2D1D8, 2E11G2, and
2C6C7 were obtained.  Although not yet characterized, these
monoclonal antibodies probably are directed against proteins
or  against  glycoproteins which  are  considered  as  major
immunogens (York, et al., 1987).  Western blotting can be used
to  characterize  MCAs which are directed against viral
proteins or against glycoproteins.  All three MCAs produced
nearly  identical  reactions  with  ILTV-infected  cells.
Fluorescence was observed mainly at the surface of the virus-
infected cells and fluorescence was also observed within the
nucleus.  These patterns of fluorescence by the monoclonal
antibodies  suggest  the reaction of monoclonal antibodies
against glycoproteins and against viral proteins because
cytoplasmic  fluorescence  suggests  the  presence  of  viral
antigens  expressed on the surface of virus-infected cells,
whereas  nuclear  fluorescence  suggests  the  reaction  of
monoclonal antibodies against viral structural proteins (York,
et,  al.,  1987).  Monoclonal  antibodies  specific  for
glycoproteins have been used to investigate the role of
glycoproteins in adsorption and penetration of cells, and cell
fusion and neutralization (Spear, 1985).
Each of the three monoclonal antibodies cross-reacted
with the other strains of ILTV,  and the fluorescence was
nearly identical to that observed against the USDA challenge
strain.  The fluorescence patterns were similar to those seen49 
with  the  USDA  challenge  strain.  All  three monoclonal
antibodies were found to not react with avian adenovirus 301
or parrot herpes virus.
While screening, some of the hybridoma supernatants were
found to react both with infected and non-infected cells,
which indicates that  some spleen cells were also producing
antibodies  against  chicken  embryo  liver  cells  or  cell
proteins.  This suggests that some cell antigens remained
after the virus purification steps and were injected with the
virus at the time of immunization.  This non-specific reaction
was also observed when the immunized mouse serum was checked
using the indirect immunofluorescent test before the mice were
sacrificed.  All 5 mice showed this serum antibody reaction
before being sacrificed.
Monoclonal antibodies 2D1D8, 2E11G2, and 2C6C7 were each
found to be of isotype IgM.  It is possible that the cells
that were responsible for producing antibodies other than IgM
could not fuse or could not survive during the process of
fusion, expansion, and cloning.
Monoclonal antibodies are an important tool for certain
other assays.  Glycoproteins are considered to be the major
immunogens for ILTV.  Identification of ILTV glycoproteins has
been done in Australia using different ILTV strains, and minor
differences have been found.  The largest glycoprotein that
has been detected measures 205Kd  (York,  et,  al.,  1987).
Identification of similar glycoproteins in ILTV strains found50 
in  the United States may be possible  if  the monoclonal
antibodies produced by this project are directed against those
glycoproteins.  The further characterization of these MCAs
remains to be done.
Different isolates of ILTV can not be differentiated by
conventional serological assays (Cover and Benton, 1958).  It
is possible that specific monoclonal antibodies could be
produced which could differentiate among virus isolates.51 
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